NIH Activities Sample Clauses

NIH Activities a. BRAIN Initiative Industry Partnership Program to Facilitate Early Access to Neuromodulation and Recording Devices for Human Clinical Studies (“Grant Program”). NIH intends to develop, fund and administer this Grant Program of cooperative agreements focusing on research using materials from corporate manufacturers of brain stimulating/recording devices, including COMPANY. This Grant Program will be for the purpose of discovering new therapeutic uses for or information regarding COMPANY Materials in order to develop new treatments for or new understanding of the human brain and brain disorders. Under this Grant Program, NIH intends to seek additional candidate brain stimulating/recording devices and associated materials from other sources, including other medical device companies. Regarding the additional candidates potentially received from other device companies, NIH intends to negotiate separate MOUs with said companies, which may be managed in a similar manner as this NIH-COMPANY MOU but not requiring any COMPANY participation. b. Procedures to be followed. NIH intends to issue a Request for Application (“RFA”) to initiate the Grant Program and will include information with respect to each COMPANY Material (defined below) to allow investigators to construct meaningful pre-applications, as described below. The NIH expects to conduct its activities under the Grant Program in two phases as follows:
Sample 1
AutoNDA by SimpleDocs
NIH Activities a. SPARC Initiative NIH-Industry Partnership towards Clinical Utility of Market- approved Devices to Support New Market Indications (“Common Fund Program”). NIH intends to develop, fund and administer this Common Fund Program through use of a combination of Cooperative Agreements and Other Transaction Authority (OTA) focusing on research using materials from corporate manufacturers of nerve stimulating/recording devices, including COMPANY. This Common Fund Program will be for the purpose of discovering new therapeutic uses for or information regarding COMPANY Materials in order to develop new treatments for or new understanding of the human peripheral control of organ function and related disorders. Under this Common Fund Program, NIH intends to seek additional candidate nerve stimulating/recording devices and associated materials from other sources, including other medical device companies. Regarding the additional candidates potentially received from other device companies, NIH intends to negotiate separate MOUs with said companies, which may be managed in a similar manner as this NIH-COMPANY MOU but not requiring any COMPANY participation. b. Procedures to be followed. NIH intends to issue a Funding Opportunity Announcement (“FOA”) to initiate the Common Fund Program and will include information with respect to each COMPANY Material (defined below) to allow investigators to prepare applications. Applicants will engage with COMPANY to develop and submit a proposal, which will include documentation of access to the relevant COMPANY Materials and confidential information pursuant to a CRA and related Project Plan. Each application submitted in response to a FOA will undergo NIH review. Applications will be selected for funding based on scientific merit, program priorities, the availability of funds, and whether a CRA (including a Project Plan) has been executed with COMPANY. Any revisions in go/no go milestones (the “Go-Forward Decision Criteria”), based on feedback from review, and the Terms and Conditions of the award will be incorporated into the NIH Notice of Award. No COMPANY devices will be transferred to any applicant unless and until the applicant is awarded. c. Administration in accordance with Law. NIH intends to administer the Common Fund Program in accordance with applicable law and agency policy, including the use of an appropriate review group to determine and ensure scientific excellence. NIH will not disclose confidential COMPANY or applica...
Sample 1

Related to NIH Activities

  • Activities Except with the prior written consent of the Board, Executive will not during his employment with the Company undertake or engage in any other employment, occupation or business enterprise, other than ones in which Executive is a passive investor. Executive may engage in civic and not-for-profit activities so long as such activities do not materially interfere with the performance of his duties hereunder.

  • Specific Activities Please give detailed information about the specific activities of the Project promoter and the Partner(s), with budget allocations 7.1 The main tasks of [name of the Project Promoter], referred to as the ‘Project Promoter’, are summarized as follows: Name Project activities Project budget 1 .... [mention the budget allocated to Project Promoter for the respective activity] EUR.... Activity 2 .... EUR... 7.2 The main input/responsibilities of [name of the Project Partner(s)], referred to as Partner 1, 2, etc., are summarized as follows: Name Project activities Project budget Partner 1... [briefly present the project activity implemented by Partner]. Activity 1 .... [mention the budget allocated to Partner 1 for the respective activity] EUR.... Activity 2 .... EUR... Name Project activities Project budget

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection xxxxx; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

  • Market Activities The Company will not, directly or indirectly, (i) take any action designed to cause or result in, or that constitutes or would reasonably be expected to constitute, the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of Common Stock or (ii) sell, bid for, or purchase Common Stock in violation of Regulation M, or pay anyone any compensation for soliciting purchases of the Placement Shares other than the Agent.

  • Typical activities Manage a large functional unit with a diverse or complex set of functions and significant resources.

  • High Risk Activities 1. The Software is not fault-tolerant and is not designed, manufactured or intended for use or resale as on-line control equipment in hazardous environments requiring fail-safe performance, such as in the operation of nuclear facilities, aircraft navigation or communication systems, air traffic control, direct life support machines, or weapons systems, in which the failure of the Software could lead directly to death, personal injury, or severe physical or environmental damage ("High Risk Activities"). Syncro and its suppliers specifically disclaim any express or implied warranty of fitness for High Risk Activities.

  • Outreach Activities a. The Agency shall conduct outreach activities for potential Clients to promote the availability of services. b. Outreach activities shall include, but are not limited to, participation in health fairs, community events, collaboration with other providers, and the posting of flyers for potential Clients. c. The Agency shall have an outreach plan and shall provide evidence of such arrangements to the Recipient upon request.

  • Marketing Activities The Borrower will not, and will not permit any of its Subsidiaries to, engage in marketing activities for any Hydrocarbons or enter into any contracts related thereto other than (i) contracts for the sale of Hydrocarbons scheduled or reasonably estimated to be produced from their proved Oil and Gas Properties during the period of such contract, (ii) contracts for the sale of Hydrocarbons scheduled or reasonably estimated to be produced from proved Oil and Gas Properties of third parties during the period of such contract associated with the Oil and Gas Properties of the Borrower and its Subsidiaries that the Borrower or one of its Subsidiaries has the right to market pursuant to joint operating agreements, unitization agreements or other similar contracts that are usual and customary in the oil and gas business and (iii) other contracts for the purchase and/or sale of Hydrocarbons of third parties (A) which have generally offsetting provisions (i.e. corresponding pricing mechanics, delivery dates and points and volumes) such that no “position” is taken and (B) for which appropriate credit support has been taken to alleviate the material credit risks of the counterparty thereto.

  • Regulatory Activities Beginning on the Effective Date and to the extent UGNX remains the Lead Development Party with respect to a particular territory, subject to and in accordance with the terms and conditions of this Agreement and the requirements of Applicable Laws, UGNX, shall: (a) use Commercially Reasonable Efforts to file (or have filed) all Regulatory Filings with respect to the Licensed Products in the Field in order to obtain Marketing Approvals in each country in the Territory and the European Territory (or to obtain the European Centralized Approval in the European Core Territory) and in order to obtain Pricing and/or Reimbursement Approvals in the Profit Share Territory; (b) respond in a timely fashion to requests for data and information from Regulatory Authorities with respect to the Licensed Products in the Field in the Territory and the European Territory; and (c) meet with officials of the Regulatory Authorities at such times as may be requested by such Regulatory Authorities with respect to the Core Development Activities (“Regulatory Activities”), provided that KHK will have primary responsibility for obtaining, and UGNX shall provide all assistance reasonably requested by KHK, in relation to Pricing and/or Reimbursement Approvals for the Licensed Products in the Field in the European Territory. For the avoidance of doubt, UGNX will be responsible for obtaining, and KHK will provide all assistance reasonably requested by UGNX, in relation to Pricing and/or Reimbursement Approvals, if any, for the Licensed Products in the Field in the Profit Share Territory as part of the UGNX Core Development Activities, it being understood that the costs incurred by UGNX in connection with such activities will be shared equally (50/50). All such Regulatory Activities will be conducted in a manner consistent with the Core Development Plan and coordinated by the JSC in accordance with Article 3. Without limiting the applicability of the foregoing and the remainder of this Article 5, UGNX shall interface with the applicable Regulatory Authority(ies) and, through the JDC, shall keep KHK reasonably informed of all material events and developments occurring in the course of the Regulatory Activities, including scheduled UGNX regulatory strategy discussions and meetings with Regulatory Authorities in the Territory and the European Territory relating to the Licensed Products in the Field.

  • Independent Activities 14.1 Except as expressly provided herein, each party shall have the free and unrestricted right to independently engage in and receive the full benefit of any and all business endeavours of any sort whatsoever, whether or not competitive with the endeavours contemplated herein without consulting the other or inviting or allowing the other to participate therein. No party shall be under any fiduciary or other duty to the other which will prevent it from engaging in or enjoying the benefits of competing endeavours within the general scope of the endeavours contemplated herein. The legal doctrines of "corporate opportunity" sometimes applied to persons engaged in a joint venture or having fiduciary status shall not apply in the case of any party. In particular, without limiting the foregoing, no party shall have any obligation to any other party as to: (a) any opportunity to acquire, explore and develop any mining property, interest or right presently owned by it or offered to it outside of the Property at any time; and (b) the erection of any mining plant, mill, smelter or refinery, whether or not such mining plant, mill, smelter or refinery treats ores or concentrates from the Property.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!